Skip to main content

Advertisement

Log in

Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson’s disease in a Swedish population

  • Movement Disorders - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Cytochrome P450 2E1 (CYP2E1), which inter alia is located in dopamine containing neurons in the substantia nigra, has been hypothesized to be of importance for the pathophysiology of Parkinson’s disease (PD), either by its production of reactive oxygen species (ROS) or by its capability to detoxify putative neurotoxins. Numerous polymorphisms in the coding and non-coding regions of the gene for this enzyme have been reported. Different variants may account for inter-individual differences in the activity of the enzyme or production of ROS. In this study, the CYP2E1 gene was examined in a control population (n = 272) and a population with PD (n = 347), using a tag-single nucleotide polymorphism (tSNP) approach founded on HapMap Data. Six tSNPs were used in the analysis and haplotype block data were obtained. In case of significance, the SNP was further examined regarding early/late age of disease onset and presence of relatives with PD. We found an association between allele and genotype frequencies of the C/G polymorphism at intron 7 (rs2070676) of this gene and PD (P value of 0.026 and 0.027, respectively). Furthermore, analysis of the rs2070676 polymorphism in subgroups of patients with age of disease onset higher than 50 years and those not having a relative with PD also demonstrated a significant difference with controls. This was seen in both genotype (corresponding to P value = 0.039 and 0.032) and allele (P = 0.027 and 0.017 respectively) frequency. As a representative of many polymorphisms or in possible linkage disequilibrium with other functional variants, it is possible that rs2070676 could influence the regulation of the enzyme. In conclusion, our results display an association between the rs2070676 polymorphism and PD. Additional investigations are needed to elucidate the importance of this polymorphism for the activity of CYP2E1 and PD susceptibility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Andersen JK (2000) What causes the build-up of ubiquitin-containing inclusions in Parkinson’s disease? Mech Ageing Dev 118(1–2):15–22

    Article  PubMed  CAS  Google Scholar 

  • Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW (1997) Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson’s disease. Lancet 350(9085):1136–1139

    Article  PubMed  CAS  Google Scholar 

  • Brockmoller J, Cascorbi I, Kerb R, Roots I (1996) Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56(17):3915–3925

    PubMed  CAS  Google Scholar 

  • Brzezinski MR, Boutelet-Bochan H, Person RE, Fantel AG, Juchau MR (1999) Catalytic activity and quantitation of cytochrome P-450 2E1 in prenatal human brain. J Pharmacol Exp Ther 289(3):1648–1653

    PubMed  CAS  Google Scholar 

  • Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I (1996) Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 6(3):203–211

    Article  PubMed  CAS  Google Scholar 

  • Daniel SE, Lees AJ (1993) Parkinson’s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39:165–172

    PubMed  CAS  Google Scholar 

  • Danko IM, Chaschin NA (2005) Association of CYP2E1 gene polymorphism with predisposition to cancer development. Exp Oncol 27(4):248–256

    PubMed  CAS  Google Scholar 

  • de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 62(1):10–15

    Article  PubMed  Google Scholar 

  • de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5):S21–S23

    PubMed  Google Scholar 

  • Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14

    PubMed  CAS  Google Scholar 

  • Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 32(6):804–812

    Article  PubMed  CAS  Google Scholar 

  • Fairbrother KS, Grove J, de Waziers I, Steimel DT, Day CP, Crespi CL, Daly AK (1998) Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 8(6):543–552

    Article  PubMed  CAS  Google Scholar 

  • Farin FM, Omiecinski CJ (1993) Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. J Toxicol Environ Health 40(2–3):317–335

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez FJ (1988) The molecular biology of cytochrome P450s. Pharmacol Rev 40(4):243–288

    PubMed  CAS  Google Scholar 

  • Hansson T, Tindberg N, Ingelman-Sundberg M, Kohler C (1990) Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system. Neuroscience 34(2):451–463

    Article  PubMed  CAS  Google Scholar 

  • Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML, Tabone M, Arinco S, Albano E, Ingelman-Sundberg M (1997) Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 51(3):370–376

    PubMed  CAS  Google Scholar 

  • Itoga S, Nomura F, Makino Y, Tomonaga T, Shimada H, Ochiai T, Iizasa T, Baba M, Fujisawa T, Harada S (2002) Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer. Alcohol Clin Exp Res 26(8 Suppl):15S–19S

    PubMed  CAS  Google Scholar 

  • Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(Suppl 3):S26–S36 (discussion S36–S28)

    Article  PubMed  CAS  Google Scholar 

  • Joshi M, Tyndale RF (2006) Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology 50(5):568–575

    Article  PubMed  CAS  Google Scholar 

  • Karuzina II, Archakov AI (1994) The oxidative inactivation of cytochrome P450 in monooxygenase reactions. Free Radic Biol Med 16(1):73–97

    Article  PubMed  CAS  Google Scholar 

  • Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D (2002) Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 97(2):230–236

    Article  PubMed  CAS  Google Scholar 

  • Ladero JM, Agundez JA, Rodriguez-Lescure A, Diaz-Rubio M, Benitez J (1996) RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Gut 39(2):330–333

    Article  PubMed  CAS  Google Scholar 

  • Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC (1997) Environmental risk factors and Parkinson’s disease: a case–control study in Taiwan. Neurology 48(6):1583–1588

    PubMed  CAS  Google Scholar 

  • Lucas D, Ferrara R, Gonzalez E, Bodenez P, Albores A, Manno M, Berthou F (1999) Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 9(3):377–388

    Article  PubMed  CAS  Google Scholar 

  • McBride OW, Umeno M, Gelboin HV, Gonzalez FJ (1987) A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucleic Acids Res 15(23):10071

    Article  PubMed  CAS  Google Scholar 

  • Montoliu C, Sancho-Tello M, Azorin I, Burgal M, Valles S, Renau-Piqueras J, Guerri C (1995) Ethanol increases cytochrome P4502E1 and induces oxidative stress in astrocytes. J Neurochem 65(6):2561–2570

    Article  PubMed  CAS  Google Scholar 

  • Nissbrandt H, Bergquist F, Jonason J, Engberg G (2001) Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: a new metabolic pathway? Synapse 40(4):294–301

    Article  PubMed  CAS  Google Scholar 

  • Pezzoli G, Antonini A, Barbieri S, Canesi M, Perbellini L, Zecchinelli A, Mariani CB, Bonetti A, Leenders KL (1995) n-Hexane-induced parkinsonism: pathogenetic hypotheses. Mov Disord 10(3):279–282

    Article  PubMed  CAS  Google Scholar 

  • Pirmohamed M, Kitteringham NR, Quest LJ, Allott RL, Green VJ, Gilmore IT, Park BK (1995) Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pharmacogenetics 5(6):351–357

    Article  PubMed  CAS  Google Scholar 

  • Riedl AG, Watts PM, Edwards RJ, Boobis AR, Jenner P, Marsden CD (1996) Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera. Brain Res 743(1–2):324–328

    Article  PubMed  CAS  Google Scholar 

  • Riedl AG, Watts PM, Jenner P, Marsden CD (1998) P450 enzymes and Parkinson’s disease: the story so far. Mov Disord 13(2):212–220

    Article  PubMed  CAS  Google Scholar 

  • Riedl AG, Watts PM, Brown CT, Jenner P (1999) P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson’s disease. Adv Neurol 80:271–286

    PubMed  CAS  Google Scholar 

  • Shahabi HN, Andersson DR, Nissbrandt H (2008) Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production. Synapse 62(5):379–388

    Article  PubMed  CAS  Google Scholar 

  • Sian J, Gerlach M, Youdim MB, Riederer P (1999) Parkinson’s disease: a major hypokinetic basal ganglia disorder. J Neural Transm 106(5–6):443–476

    Article  PubMed  CAS  Google Scholar 

  • Sohda T, Shimizu M, Kamimura S, Okumura M (1993) Immunohistochemical demonstration of ethanol-inducible P450 2E1 in rat brain. Alcohol Alcohol Suppl 1B:69–75

    PubMed  CAS  Google Scholar 

  • Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5(7):895–931

    Article  PubMed  CAS  Google Scholar 

  • Staudt H, Lichtenberger F, Ullrich V (1974) The role of NADH in uncoupled microsomal monoxygenations. Eur J Biochem 46(1):99–106

    Article  PubMed  CAS  Google Scholar 

  • The International HapMap Project (2003) Nature 426(6968):789–796

    Google Scholar 

  • Tindberg N, Baldwin HA, Cross AJ, Ingelman-Sundberg M (1996) Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury. Mol Pharmacol 50(5):1065–1072

    PubMed  CAS  Google Scholar 

  • Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez FJ (1988) Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 27(25):9006–9013

    Article  PubMed  CAS  Google Scholar 

  • Upadhya SC, Tirumalai PS, Boyd MR, Mori T, Ravindranath V (2000) Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch Biochem Biophys 373(1):23–34

    Article  PubMed  CAS  Google Scholar 

  • Vaglini F, Pardini C, Viaggi C, Bartoli C, Dinucci D, Corsini GU (2004) Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced mouse model of Parkinson’s disease. J Neurochem 91(2):285–298

    Article  PubMed  CAS  Google Scholar 

  • Viaggi C, Pardini C, Vaglini F, Corsini GU (2006) Cytochrome P450 and Parkinson’s disease: protective role of neuronal CYP 2E1 from MPTP toxicity. J Neural Transm Suppl 70:173–176

    Article  PubMed  CAS  Google Scholar 

  • Wang J, Liu Z, Chan P (2000) Lack of association between cytochrome P450 2E1 gene polymorphisms and Parkinson’s disease in a Chinese population. Mov Disord 15(6):1267–1269

    Article  PubMed  CAS  Google Scholar 

  • Warner TT, Schapira AH (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53(Suppl 3):S16–S23 (discussion S23–S15)

    Article  PubMed  CAS  Google Scholar 

  • Watts PM, Riedl AG, Douek DC, Edwards RJ, Boobis AR, Jenner P, Marsden CD (1998) Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience 86(2):511–519

    Article  PubMed  CAS  Google Scholar 

  • Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R (2007) Inflammation in Parkinson’s diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 13(18):1925–1928

    Article  PubMed  CAS  Google Scholar 

  • Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ (2000) Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 53(2):88–93

    Article  PubMed  CAS  Google Scholar 

  • Wu X, Shi H, Jiang H, Kemp B, Hong WK, Delclos GL, Spitz MR (1997) Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 18(5):967–973

    Article  PubMed  CAS  Google Scholar 

  • Wu RM, Cheng CW, Chen KH, Shan DE, Kuo JW, Ho YF, Chern HD (2002) Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson’s disease in Taiwanese. J Neural Transm 109(11):1403–1414

    Article  PubMed  CAS  Google Scholar 

  • Yang M, Tsuang J, Yvonne Wan YJ (2007) A haplotype analysis of CYP2E1 polymorphisms in relation to alcoholic phenotypes in Mexican Americans. Alcohol Clin Exp Res 31(12):1991–2000

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The study was supported by the Swedish Research Council, Åhlén’s Foundation, Swedish Parkinson Foundation, Swedish Brain Power Initiative, Swedish Brain Foundation, Hållstens Forskningsstiftelse, Björn Oscarssons stiftelse and Karolinska Institutet Funds.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Niazi Shahabi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niazi Shahabi, H., Westberg, L., Melke, J. et al. Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson’s disease in a Swedish population. J Neural Transm 116, 567–573 (2009). https://doi.org/10.1007/s00702-009-0221-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-009-0221-1

Keywords

Navigation